Effects of combined treatment with niftolide and low doses of antitumor estrogen preparation, chlorotrianizene, on rat prostate

a significant:atrophy of the ventral prostate (VP), and particularly its ep ithelium, as well as of other accessory sexual glands, were found in the ra ts after combined administration of the cell androgen receptor blocker, nif tolide (flutamide, 10 mg/kg b.w. per os), and estrogenic antitumor drug, ch lorotrianizene (0,2 mg/kg b.w. per os) during 10 days. The VP gland size va lues were reduced by 74%, and the VP weight decreased by 63,1% alongside wi th decline of total DNA, RNA and protein contents per organ by 39,6, 78,7 a nd 64,6% respectively; These changes were moderate or absent under separate administration of the drugs. The potentiation of the antiandrogenic effect s of niftolide on the VP and other tissues by chlorotrianizene minidose can be explained by prevention of niftolide-induced rise of LH and testosteron e release, and, probably, by direct action of chlorotrianizene on the tissu es.